Study product adherence measurement in the iPrEx placebo-controlled trial: Concordance with drug detection

Journal of Acquired Immune Deficiency Syndromes

Volumn 66, Issue 5, 2014, Pages 530-537

  Amico, K Rivet ^a,b   Marcus, Julia L ^c   McMahan, Vanessa ^c   Liu, Albert ^d   Koester, Kimberly A ^e   Goicochea, Pedro ^b,f   Anderson, Peter L ^g   Glidden, David ^d   Guanira, Juan ^f   Grant, Robert ^c  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b Applied Health Research   (United States)

^c GLADSTONE INSTITUTES   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f Investigaciones Medicas en Salud   (Peru)

^g UNIVERSITY OF COLORADO   (United States)

Author keywords

Drug concentration; Drug detection; iPrEx; PrEP adherence; Self report

Indexed keywords

EMTRICITABINE; PLACEBO; TENOFOVIR DISOPROXIL;

ADULT; ARTICLE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; COMPUTER ASSISTED THERAPY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; FEMALE; HEALTH SURVEY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MEASUREMENT ACCURACY; MEDICAL RECORD; MEDICATION COMPLIANCE; MULTICENTER STUDY; PATIENT COMPLIANCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHARMACY; PILL; PREDICTIVE VALUE; PRIORITY JOURNAL; SELF REPORT; SEMI STRUCTURED INTERVIEW; UNITED STATES;

ADULT; ANTI-HIV AGENTS; FEMALE; HIV INFECTIONS; HUMANS; MALE; MEDICATION ADHERENCE; TRANSGENDERED PERSONS; WORLD HEALTH; YOUNG ADULT;

EID: 84904470795     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000000216     Document Type: Article

References (21)

1. van der Straten A, Van Damme L, Haberer JE, et al. Unraveling the divergent results of pre-exposure prophylaxis trials for HIV prevention. AIDS. 2012;26:F13-F19.
2. Thompson MA, Mugavero MJ, Amico KR, et al. Guidelines for improving entry into and retention in care and antiretroviral adherence for persons with HIV: evidence-based recommendations from an International Association of Physicians in AIDS Care panel. Ann Intern Med. 2012; 156:817-833; W-284-W-294.
3. Williams AB, Amico KR, Bova C, et al. A proposal for quality standards for measuring medication adherence in research. AIDS Behav. 2013;17: 284-297.
4. Van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367:411-422.
5. Marrazzo J, Ramjee G, Nair G, et al. Pre-exposure prophylaxis for HIV in women: daily oral tenofovir, oral tenofovir/emtricitabine, or vaginal tenofovir gel in the VOICE study (MTN 003). Presented at: 20th Conference on Retroviruses and Opportunistic Infections, Altanta, GA: 2013.
6. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010; 363:2587-2599.
7. Anderson PL, LJ, Buchbinder S, et al. Interpreting detection rates of intracellular emtricitabine-triphosphate (FTC-tp) and tenofovir-diphosphate (TFV-dp) in the IPrEx Trial. Presented at: 18th Conference on Retroviruses and Opportunistic Infections (CROI), Boston, MA: 2011.
8. Anderson PL, Glidden DV, Liu A, et al. Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med. 2012;4:151ra125.
9. DiMatteo MR, Giordani PJ, Lepper HS, et al. Patient adherence and medical treatment outcomes: a meta-analysis. Med Care. 2002;40: 794-811.
10. Oh DL, Sarafian F, Silvestre A, et al. Evaluation of adherence and factors affecting adherence to combination antiretroviral therapy among White, Hispanic, and Black men in the MACS Cohort. J Acquir Immune Defic Syndr. 2009;52:290-293.
11. Thirumurthy H, Siripong N, Vreeman RC, et al. Differences between self-reported and electronically monitored adherence among patients receiving antiretroviral therapy in a resource-limited setting. AIDS. 2012;26:2399-2403.
12. Shi L, Liu J, Fonseca V, et al. Correlation between adherence rates measured by MEMS and self-reported questionnaires: a meta-analysis. Health Qual Life Outcomes. 2010;8:99.
13. Shi L, Liu J, Koleva Y, et al. Concordance of adherence measurement using self-reported adherence questionnaires and medication monitoring devices. Pharmacoeconomics. 2010;28:1097-1107.
14. Minnis AM, Gandham S, Richardson BA, et al. Adherence and acceptability in MTN 001: a randomized cross-over trial of daily oral and topical tenofovir for HIV prevention in women. AIDS Behav. 2013;17: 737-747.
15. Wilson IB, Carter AE, Berg KM. Improving the self-report of HIV antiretroviral medication adherence: is the glass half full or half empty? Curr HIV/AIDS Rep. 2009;6:177-186.
16. Saethre E, Stadler J. Malicious whites, greedy women, and virtuous volunteers: negotiating social relations through clinical trial narratives in South Africa. Med Anthropol Q. 2013;27:103-120.
17. Amico K, McMahan V, Goicochea P, et al. Supporting study product use and accuracy in self-report in the iPrEx study: next step counseling and neutral assessment. AIDS Behav. 2012;16:1243-1259.
18. Liu A GD, Anderson P, Amico KR, McMahan V, Mehrotra M, Lama J, MacRae J, Hinojosa JC, Montoya O, Veloso V, Schechter M, Kallas E, Chariyalerstak S, Bekker LG, Mayer K, Buchbinder S, Grant R, iPrEx Study Team. Patterns and Correlates of PrEP Drug Detection among MSM and Transgender Women in the Global iPrEx Study. Presented at: 9th Annual HIV Treatment and Prevention Adherence Conference of the International Association of Providers in AIDS Care. Miami, FL; June 2014.
19. Gilmore HJ, Liu A, Koester KA, et al. Participant experiences and facilitators and barriers to pill Use among men who have sex with men in the iPrEx pre-exposure prophylaxis trial in San Francisco. AIDS Patient Care STDS. 2013;27:560-566.
20. Tangmunkongvorakul A, Chariyalertsak S, Amico KR, et al. Facilitators and barriers to medication adherence in an HIV prevention study among men who have sex with men in the iPrEx study in Chiang Mai, Thailand. AIDS Care. 2012;25:961-967.
21. Ambia J, Agot K. Barriers and facilitators of adherence in userdependent HIV prevention trials, a systematic review. Int STD Res Rev. 2013;1:12-29.